ImmuneOncia Therapeutics, Inc. Logo

ImmuneOncia Therapeutics, Inc.

A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.

424870 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 용인시 기흥구 탑실로35번길 25, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ImmuneOncia Therapeutics, Inc. is a clinical-stage, immuno-oncology-centric biopharmaceutical company dedicated to developing cutting-edge immunotherapies for cancer treatment. Established in 2016 as a joint venture between Yuhan Corporation and Sorrento Therapeutics, the company leverages expertise in drug development and antibody engineering. ImmuneOncia's pipeline focuses on developing immune checkpoint inhibitors targeting T cells and macrophages. Its portfolio includes IMC-001, its lead candidate, and IMC-002, a fully human anti-CD47 monoclonal antibody for various cancers.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 887.8 KB
2025-05-30 00:00
Share Issue/Capital Change
주식매수선택권행사
Korean 43.9 KB
2025-05-23 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 102.9 KB
2025-05-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-05-12 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 323.5 KB
2025-04-30 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 525.5 KB
2025-04-30 00:00
Prospectus
[기재정정]투자설명서
Korean 3.9 MB
2025-04-28 00:00
Prospectus
투자설명서
Korean 3.3 MB
2025-04-18 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.4 MB
2025-04-17 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 4.2 MB
2025-04-04 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.9 MB
2025-04-02 00:00
Registration Form
[기재정정]증권신고서(지분증권)
Korean 3.5 MB
2025-03-28 00:00
Annual / Quarterly Financial Statement
감사보고서 (2024.12)
Korean 397.2 KB
2025-03-14 00:00
Registration Form
증권신고서(지분증권)
Korean 3.1 MB

Automate Your Workflow. Get a real-time feed of all ImmuneOncia Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for ImmuneOncia Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.